Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Real-World Data and Genitourinary Cancer

View overview page
Smoking-associated genomic alterations linked to poorer outcomes in metastatic prostate cancer 2:19
Smoking-associated genomic alterations linked to poorer outcomes in metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
ctDNA monitoring & outcomes in bladder cancer treated with EV & pembrolizumab 3:18
ctDNA monitoring & outcomes in bladder cancer treated with EV & pembrolizumab
Vadim Koshkin • 1 Jun 2026
Real-world outcomes by HER2 expression in la/mUC in the SGNDV-003 study 5:25
Real-world outcomes by HER2 expression in la/mUC in the SGNDV-003 study
Vadim Koshkin • 1 Jun 2026
Molecular basis of NCCN risk reclassification in early prostate cancer 2:01
Molecular basis of NCCN risk reclassification in early prostate cancer
Daniel Keizman • 31 May 2026
Decision regret & toxicity perception following adjuvant IO in kidney cancer 2:14
Decision regret & toxicity perception following adjuvant IO in kidney cancer
Elizabeth Nally • 30 May 2026
Decision regret in patients with kidney cancer following adjuvant therapy 0:57
Decision regret in patients with kidney cancer following adjuvant therapy
Elizabeth Nally • 30 May 2026
Challenges of discussing adjuvant therapy with patients with kidney cancer 1:14
Challenges of discussing adjuvant therapy with patients with kidney cancer
Elizabeth Nally • 30 May 2026
Real-world post–177Lu-PSMA-617 treatment patterns & outcomes in mCRPC 1:08
Real-world post–177Lu-PSMA-617 treatment patterns & outcomes in mCRPC
Ben Tran • 28 Feb 2026
Cardiovascular risk factors with hormonal therapies in prostate cancer 2:41
Cardiovascular risk factors with hormonal therapies in prostate cancer
Dalia Kaakour • 27 Feb 2026
Real-world belzutifan efficacy in metastatic clear cell renal cell carcinoma 4:16
Real-world belzutifan efficacy in metastatic clear cell renal cell carcinoma
Chris Labaki • 27 Feb 2026
Using early QoL data to identify patients with high-risk RCC 0:55
Using early QoL data to identify patients with high-risk RCC
Michael Harrison • 26 Feb 2026
ODYSSEY: real-world QOL outcomes on IO regimens in metastatic RCC 2:30
ODYSSEY: real-world QOL outcomes on IO regimens in metastatic RCC
Michael Harrison • 26 Feb 2026
177Lu-PSMA-617 after sipuleucel-T in mCRPC: PRECISION analysis 1:39
177Lu-PSMA-617 after sipuleucel-T in mCRPC: PRECISION analysis
Neal Shore • 26 Feb 2026
Prognostic impact of PSA thresholds in mHSPC after ADT-ARPI 2:27
Prognostic impact of PSA thresholds in mHSPC after ADT-ARPI
Michael Ong • 1 Jun 2025
Clonal hematopoiesis monitoring as a future biomarker in mCRPC 1:04
Clonal hematopoiesis monitoring as a future biomarker in mCRPC
Aslı Doğa Munzur • 31 May 2025
ODESSY: real world outcomes on active surveillance in mRCC 3:37
ODESSY: real world outcomes on active surveillance in mRCC
Michael Harrison • 31 May 2025
The content of VJOncology is intended for healthcare professionals